PortfoliosLab logoPortfoliosLab logo
PVLA vs. DBVT
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

PVLA vs. DBVT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Palvella Therapeutics, Inc (PVLA) and DBV Technologies S.A. (DBVT). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

PVLA vs. DBVT - Yearly Performance Comparison


2026 (YTD)20252024
PVLA
Palvella Therapeutics, Inc
19.09%772.25%-6.47%
DBVT
DBV Technologies S.A.
8.97%520.39%-4.04%

Fundamentals

EPS

PVLA:

-$3.75

DBVT:

-$6.53

Total Revenue (TTM)

PVLA:

$0.00

DBVT:

$511.00K

Gross Profit (TTM)

PVLA:

$0.00

DBVT:

-$12.87M

EBITDA (TTM)

PVLA:

-$14.75M

DBVT:

-$116.13M

Returns By Period

In the year-to-date period, PVLA achieves a 19.09% return, which is significantly higher than DBVT's 8.97% return.


PVLA

1D
12.64%
1M
-7.68%
YTD
19.09%
6M
98.84%
1Y
345.34%
3Y*
5Y*
10Y*

DBVT

1D
6.80%
1M
-0.48%
YTD
8.97%
6M
108.90%
1Y
206.30%
3Y*
7.32%
5Y*
-17.05%
10Y*
-24.27%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Palvella Therapeutics, Inc

DBV Technologies S.A.

Often compared with DBVT:
DBVT vs. VOODBVT vs. TRVI

Return for Risk

PVLA vs. DBVT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PVLA
PVLA Risk / Return Rank: 9797
Overall Rank
PVLA Sharpe Ratio Rank: 9898
Sharpe Ratio Rank
PVLA Sortino Ratio Rank: 9595
Sortino Ratio Rank
PVLA Omega Ratio Rank: 9292
Omega Ratio Rank
PVLA Calmar Ratio Rank: 9999
Calmar Ratio Rank
PVLA Martin Ratio Rank: 9898
Martin Ratio Rank

DBVT
DBVT Risk / Return Rank: 9393
Overall Rank
DBVT Sharpe Ratio Rank: 9393
Sharpe Ratio Rank
DBVT Sortino Ratio Rank: 9292
Sortino Ratio Rank
DBVT Omega Ratio Rank: 8787
Omega Ratio Rank
DBVT Calmar Ratio Rank: 9797
Calmar Ratio Rank
DBVT Martin Ratio Rank: 9494
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PVLA vs. DBVT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Palvella Therapeutics, Inc (PVLA) and DBV Technologies S.A. (DBVT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


PVLADBVTDifference

Sharpe ratio

Return per unit of total volatility

3.95

2.35

+1.61

Sortino ratio

Return per unit of downside risk

3.67

3.06

+0.61

Omega ratio

Gain probability vs. loss probability

1.44

1.35

+0.09

Calmar ratio

Return relative to maximum drawdown

11.48

7.27

+4.21

Martin ratio

Return relative to average drawdown

25.99

15.25

+10.74

PVLA vs. DBVT - Sharpe Ratio Comparison

The current PVLA Sharpe Ratio is 3.95, which is higher than the DBVT Sharpe Ratio of 2.35. The chart below compares the historical Sharpe Ratios of PVLA and DBVT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


PVLADBVTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

3.95

2.35

+1.61

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.18

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.28

Sharpe Ratio (All Time)

Calculated using the full available price history

5.86

-0.23

+6.09

Correlation

The correlation between PVLA and DBVT is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

PVLA vs. DBVT - Dividend Comparison

Neither PVLA nor DBVT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

PVLA vs. DBVT - Drawdown Comparison

The maximum PVLA drawdown since its inception was -31.48%, smaller than the maximum DBVT drawdown of -99.52%. Use the drawdown chart below to compare losses from any high point for PVLA and DBVT.


Loading graphics...

Drawdown Indicators


PVLADBVTDifference

Max Drawdown

Largest peak-to-trough decline

-31.48%

-99.52%

+68.04%

Max Drawdown (1Y)

Largest decline over 1 year

-29.93%

-32.58%

+2.65%

Max Drawdown (5Y)

Largest decline over 5 years

-96.41%

Max Drawdown (10Y)

Largest decline over 10 years

-99.52%

Current Drawdown

Current decline from peak

-15.97%

-95.77%

+79.80%

Average Drawdown

Average peak-to-trough decline

-9.68%

-69.87%

+60.19%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.22%

15.54%

-2.32%

Volatility

PVLA vs. DBVT - Volatility Comparison

Palvella Therapeutics, Inc (PVLA) and DBV Technologies S.A. (DBVT) have volatilities of 21.02% and 20.16%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


PVLADBVTDifference

Volatility (1M)

Calculated over the trailing 1-month period

21.02%

20.16%

+0.86%

Volatility (6M)

Calculated over the trailing 6-month period

63.51%

63.74%

-0.23%

Volatility (1Y)

Calculated over the trailing 1-year period

88.04%

88.99%

-0.95%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

84.82%

92.97%

-8.15%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

84.82%

85.43%

-0.61%

Financials

PVLA vs. DBVT - Financials Comparison

This section allows you to compare key financial metrics between Palvella Therapeutics, Inc and DBV Technologies S.A.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober00
(PVLA) Total Revenue
(DBVT) Total Revenue
Values in USD except per share items